# AFPᶜ³³²T in Advanced HCC

> **NCT03132792** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Adaptimmune** · enrollment: 45 (actual)

## Conditions studied

- Hepatocellular Cancer
- AFP Expressing Tumors

## Interventions

- **GENETIC:** Autologous genetically modified AFPᶜ³³²T cells

## Key facts

- **NCT ID:** NCT03132792
- **Lead sponsor:** Adaptimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-08
- **Primary completion:** 2021-07-07
- **Final completion:** 2025-12-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03132792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03132792, "AFPᶜ³³²T in Advanced HCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03132792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*